Clinical features and genetic spectrum of a multicenter Chinese cohort with myotonic dystrophy type 1.

"Declarations Ethics approval and consent to participateThe study was approved by the ethic committee of Huashan Hospital and other participating hospitals (2020–008) and registered on clinicaltrials.gov (NCT06101940). Written informed consent was acquired from every participant according to the Declaration of Helsinki. Consent for publicationAll authors have consented to the publication of this manuscript. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This study was funded by China’s National Key R&D Program (No. 2022YFC3501303, 2022YFC3501305), National Natural Science Foundation of China (No. 82071410, 82001335), Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01), and ZJLab."

"Patients with DM1 were enrolled from January 2020 to April 2023 through the collaborative efforts of the Pan-Yangtze River Delta Alliance for Neuromuscular Disorders (PYDAN) network in China [–]. Written informed consent to be included in the study was obtained from all patients. The study was approved by the ethics committee of Huashan Hospital (2020–008) and other participating hospitals and was registered on clinicaltrials.gov (NCT06101940). The clinical diagnosis of DM1 was based on classical clinical presentations, electromyography, and family history. Declarations: Ethics approval and consent to participateThe study was approved by the ethic committee of Huashan Hospital and other participating hospitals (2020–008) and registered on clinicaltrials.gov (NCT06101940). Written informed consent was acquired from every participant according to the Declaration of Helsinki.: Consent for publicationAll authors have consented to the publication of this manuscript.: Competing interestsThe authors declare that they have no competing interests. Ethics approval and consent to participate: The study was approved by the ethic committee of Huashan Hospital and other participating hospitals (2020–008) and registered on clinicaltrials.gov (NCT06101940). Written informed consent was acquired from every participant according to the Declaration of Helsinki."